AI philanthropy funds neglected health research

AI companies are beginning to channel money, compute credits and technical support into public‑good scientific and educational projects that market actors avoid. These partnerships can accelerate research on low‑commercial‑value diseases (for example, HPV and preeclampsia), build language resources for underrepresented regions, and provide public datasets and tooling intended for open release. — This shifts how we think about who produces research and public infrastructure: private AI firms (often with philanthropic partners) are becoming underwriters of public‑goods science, with implications for agenda setting, governance, and sovereignty.